By Mark Chael --
On April 29, 2009, ImmunoCellular Therapeutics, Ltd. announced that the U.S. Patent and Trademark Office issued Patent No. 7,498,129, which relates to the company's monoclonal antibody platform. The '129 patent is entitled "Myeloma Cell and Ovarian Cancer Cell Surface Glycoproteins, Antibodies Thereto, and Uses Thereof," and according to ImmunoCellular, is directed to the use of the company's antibodies to measure the effectiveness of proposed treatments for multiple myeloma and ovarian cancer.
Claim 1 of the '129 patent reads as follows:
a) measuring changes in the level of the antigen recognizable by a monoclonal antibody or antigen binding fragment thereof in a bodily fluid sample from a patient undergoing therapy, wherein said monoclonal antibody is produced by the hybridoma cell line deposited at the American Type Culture Collection having accession No. PTA-450; and
b) correlating the change in the level with the effectiveness of said therapy, wherein a decrease in the level indicates a reduced tumor burden.
In 2007, ImmunoCellular acquired a portion of its monoclonal antibody-related technology from Molecular Discoveries. One such monoclonal antibody, ICT-109, targets small cell lung cancer (SCLC) and pancreatic cancer. ICT-109 is currently in pre-clinical development, and is useful as a diagnostic reagent to prescreen patients for the specific antigens to which it binds. According to ImmunoCellular, this antibody has shown encouraging preliminary data in pre-clinical studies and may be ready to enter clinical trials in the near future for SCLC and/or pancreatic cancer.
According to the assignment database at the USPTO, ImmunoCellular is the assignee of record on at least seven patents and one published patent application.